

Project Title	Funding	Strategic Plan Objective	Institution
Developing treatment, treatment validation, and treatment scope in the setting of an autism clinical trial	\$0	Q4.L.A	University of Medicine & Dentistry of New Jersey
A multi-site double-blind placebo-controlled trial of memantine vs. placebo in children with autism	\$0	Q4.L.A	Holland Bloorview Kids Rehabilitation Hospital
Intranasal oxytocin for the treatment of children and adolescents with autism spectrum disorders (ASD)	\$0	Q4.S.C	Holland Bloorview Kids Rehabilitation Hospital
Exploration of resting-state network dynamics in autism spectrum disorders	\$0	Q4.Other	Harvard University
The use of non-invasive brain stimulation to improve social relating in autism spectrum disorders	\$0	Q4.S.F	Monash University
Developing treatment, treatment validation, and treatment scope in the setting of an autism clinical trial	\$0	Q4.L.A	University of Medicine & Dentistry of New Jersey - Robert Wood Johnson Medical School
Developing treatment, treatment validation, and treatment scope in the setting of an autism clinical trial	\$0	Q4.L.A	University of Medicine & Dentistry of New Jersey - Robert Wood Johnson Medical School
A randomized, controlled trial of intranasal oxytocin as an adjunct to behavioral therapy for autism spectrum disorder	\$0	Q4.S.C	Massachusetts General Hospital
Metabolic signature of antipsychotics used in the treatment of autism	\$0	Q4.L.C	University of Cincinnati
Metabolic factors affecting gamma synchrony	\$25,000	Q4.S.C	University of Louisville
Leadership Education in Neurodevelopmental Disabilities	\$26,000	Q4.Other	University of Pennsylvania
Trial of a glutamate antagonist in the treatment of OCD and autistic disorders	\$33,959	Q4.L.A	National Institutes of Health
Randomized controlled trial of oxytocin treatment for social deficits in children with autism	\$50,600	Q4.L.A	Stanford University
Randomized phase 2 trial of RAD001 (an mTOR inhibitor) in patients with tuberous sclerosis complex	\$65,000	Q4.L.A	Boston Children's Hospital
Treatment of children with ASD and epileptiform EEG with divalproex sodium	\$68,088	Q4.S.A	Boston Children's Hospital
Evaluation of a melanocortin agonist to improve social cognition in ASD.	\$74,675	Q4.L.A	University of Sydney
Association of cholinergic system dysfunction with autistic behavior in fragile X syndrome: Pharmacologic and imaging probes	\$92,469	Q4.L.A	Stanford University
Mirtazapine treatment of anxiety in children and adolescents with pervasive developmental disorders	\$94,242	Q4.L.C	Indiana University
New experimental medicine studies: Fast-Fail Trials in autism spectrum disorders	\$115,889	Q4.L.A	University of California, Los Angeles
Pharmacotherapy of pervasive developmental disorders	\$182,830	Q4.L.C	Indiana University-Purdue University Indianapolis
Predictors of effects of propranolol on language & connectivity in autism	\$192,150	Q4.S.F	University of Missouri
Building a selective inhibitory control tone in autism: An rTMS study	\$219,780	Q4.Other	University of Louisville

Project Title	Funding	Strategic Plan Objective	Institution
Early pharmacotherapy guided by biomarkers in autism (supplement)	\$260,000	Q4.S.F	Wayne State University
3/3-Atomoxetine placebo and parent training in autism	\$263,639	Q4.S.F	University of Rochester
1/3-Atomoxetine placebo and parent training in autism	\$269,976	Q4.S.F	University of Pittsburgh
ACE Center: Augmenting language interventions for ASD: A translational approach	\$281,072	Q4.L.A	University of California, Los Angeles
Controlled trial of sertraline in young children with Fragile X Syndrome	\$285,970	Q4.L.A	University of California, Davis
2/3-Atomoxetine placebo and parent training in autism	\$350,730	Q4.S.F	The Ohio State University
Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART)	\$634,243	Q4.S.F	Medical University of South Carolina
ACE Network: Early pharmacotherapy guided by biomarkers in autism	\$1,996,122	Q4.S.F	Wayne State University
Autism Intervention Research Network on Physical Health (AIR-P network)	\$2,079,996	Q4.S.A	Massachusetts General Hospital
ACE Network: Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors (SOARS-B)	\$2,589,347	Q4.L.A	University of North Carolina at Chapel Hill

